Depletion of blood supply and cost due to indeterminate donations at the Guillermo Almenara Irigoyen National Hospital
DOI:
https://doi.org/10.24265/horizmed.2017.v17n1.06Keywords:
Gray zone, Blood donation, Infectious markers, ScreeningAbstract
Objective: To evaluate the depletion of blood supply and the cost of indeterminate donations at the Guillermo Almenara Irigoyen National Hospital during 2014.
Materials and methods: Retrospective cross-sectional study and cost-utility analysis in donations with gray zone results (sample value/cut-off value between the limits > 0.85 and < 1) after serological screening for the seven infectious markers (HIV, HBsAg, HBcAb, HCV, HTLV-1/2, SYPHILIS and CHAGAS) and simultaneous determination of HIV Ag/Ab combo, by fourth-generation ELISA. The data were coded and tabulated from the e-Delphyn® system. The cost analysis was performed considering the current exchange rate.
Results: Out of 9,560 donations, 20.7% (1977 donations) were gray zone results, resulting in a loss of 863.9 liters of blood and 92,640 USD. HbcAb with 10.18% (973 indeterminate results) and anti-HIV with 0.39% (37 indeterminate results) were the results with the highest and lowest seroprevalence, respectively (p<0.05). No significant difference was found between anti-HIV and HIV Ag/Ab combo markers (p=0.776).
Conclusions: It was demonstrated that >800 liters of discarded blood generated >90 thousand USD of cost for undetermined donations causing economic damage to the hospital budget and a decrease in the blood supply available for the treatment of patients at the Guillermo Almenara Irigoyen National Hospital.
Downloads
References
Goodnough LT, Shander A, Brencher ME. Transfusion medicine: looking to the future. Lancet 2003;361 (9352):161–9.
Callery MF, Nevalainen DE, Kirst TM. Quality systems and total process control in blood banking. Transfusión.1994; 34 (10):899–906.
Choudhury N. Transfusion transmitted infections: How many more? Asian J Transfus Sci. 2010; 4(2): 71–72.
Vega MC, Montoro AJ. Manual de Medicina Transfusional. España: Mosby-Doyma; 1994.
Allan SR Jr. Administrative Manual Vol I, II, III. Bethesda, MD: American Association of Blood Banks. 1996.
Bihl F, Castelli D, Marincola F, Dodd R, Brander C. Transfusiontransmitted infections. J Transl Med. 2007; 5: 25.
Chiodini PL, Hartley S, Hewitt PE, Barbara JA, Lalloo K, Bligh J, et al. Evaluation of a malaria antibody ELISA and its value in reducing potential wastage of red cell donations from blood donors exposed to malaria, with a note on a case of transfusion-transmitted malaria. Vox Sang. 1997;73(3):143– 148.
Aguirre GG, Martínez AJ, Arenas EI. Resultados en zona gris del tamizaje para VIH y VHC, pueden indicar seroconversión inmediata. Rev Mex Patol Clin. 2005; 52(1): 63-68.
Moya SJ, Julcamanyan TE. Seroprevalence infectious markers causing loss of donations in the blood bank service in Hospital Nacional Docente Madre Niño San Bartolome 2008-2013. Horiz Med.2014; 14(4): 6-14.
Velásquez A, Cachay C, Munayco C, Poquioma E, Espinoza R, Seclén Y. La Carga de Enfermedad y Lesiones en el Perú. Perú: Ministerio de Salud; 2009.
Fano VR, Hernández PM, Jiménez DE, Longres MA. Marcadores serológicos causantes de pérdidas de donaciones. Rev Cubana Med Milit.2000;29(1):41-5.
Pan-American Health Organization. Supply of blood for transfusion in Latin American and Caribbean countries 2012 and 2013. Washington, DC : PAHO; 2015.
Ministerio de Salud. Sistema de Gestión de la Calidad del PRONAHEBAS. Manual de Calidad. Norma Técnica. No 011– MINSA/ DGSP–V. 01. 2004.
Barbara JA. Challenges in transfusion microbiology. Transfus Med Rev. 1993;7(2):96-103.
Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. N Engl J Med.1996; 334:1685-1690.
Pan American Health Organization. Supply of Blood for Transfusion in the Caribbean and Latin American Countries in 2006-2007: Progress since 2005 of the Regional Plan of Action for Transfusion Safety. Washington, DC : PAHO; 2009.
Sellors J, Zimic-Vincetic M, Howard M, Mahony JB, Chernesky MA. Predictors of positivity for hepatitis B and the derivation of a selective screening rule in a Canadian sexually transmitted diseases clinic. J Clin Virol. 1998; 11(1):85-91.
Blejer JL, Carreras VL, Salamone HJ. Riesgo de Transmisión de Infecciones por Vía Transfusional. MEDICINA.2002; 62: 259-278.
Grifols EJ, Martin VC, Hernández SJ, Pujol BM, Grifols RJ, García RE. Seguridad en Medicina Transfusional. Menarini Diagnóstics. España: Pecalo; 1998.
Blejer JL, Sartor PA, Botasso O, Salome HJ, Leguizamón MS. Trans-sialidase inhibition assay for the detection of Trypanosoma cruzi infection in blood donor samples from Argentina. Vox Sang.2008;95(3): 189-196.
Zur Hausen H. The search for infectious causes of human cancers: Where and why. Virology.2009;392 (1): 1–10.
Khabbaz RF, Heneine W, Grindon A, Hartley TM, Shulman G, Kaplan J. Indeterminate HTLV serologic results in U.S. blood donors: are they due to HTLV-I or HTLV-II? J Acquir Immune Defic Syndr. 1992;5(4):400-4.
Dood RY. Hepatitis C virus, antibodies, and infectivity: parodox, pragmatism, and policy. Am J Clin Pathol. 1992; 97: 4-6.
Bush MP, Kleinman SH, Jackson B, Stramer SL, Hewlett I, Preston S. Nuclei acid amplification testing of blood donor for transfusion-transmitted infectious diseases: report of the interorganizational task force on nuclei acid amplification testing in blood donor. Transfusion 2000;40(2):143-159.
Melve GK, Myrmel H, Eide GE, Hervig T. Evaluation of the persistence and characteristics of indeterminate reactivity against hepatitis C virus in blood donors. Transfusion. 2009;49(11):2359-65.
Schoofs M. SIDA, la agonía de África. Merck Sharp & Dohme. USA: The Village Voice; 2000.
Busch MP, Lee L, Satten GA, Henrard DR, Farzadegan H, Nelson KE, et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion.1995; 35(2): 91-97.
Saville RD, Constantine NT, Cleghorn FR, Jack N, Bartholomew C, Edwards J, et al. Fourth Generation Enzyme-Linked Immunosorbent Assay for the Simultaneous detection of Human Immunodeficiency Virus Antigen and Antibody. J Clin Microbiol. 2001;39(7):2518-24.
Yilmaz G. Diagnosis of HIV infection and laboratory monitoring of its therapy. J Clin Virol. 2001 ; 21(3): 187-96.
Clinical and Laboratory Standards Institute (CLSI). Interference Testing in Clinical Chemistry; Approved Guideline - Second Edition. CLSI document EP7-A2. Wayne, PA: CLSI; 2005.
Beelaert G, Fransen K. Evaluation of a rapid and simple fourthgeneration HIV screening assay for qualitative detection of HIV p24 antigen and/or antibodies to HIV-1 and HIV-2. J Virol Methods. 2010; 168(1):218-22.
Sánchez AS, Gonzales NP, Alvarez VJ. Costos en la Transfusión Sanguínea. Rev Mex Anest. 2000;23(2): 66-70.
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
